FGFR2

GENETIC2 trials

Sponsors

The Affiliated Hospital of Qingdao University, Quintiles

Conditions

Advanced, Relapsed Gastric or Gastro-oesophageal Junction CarcinomaGastric or Gastro-oesophageal Junction CarcinomaSecond-line Therapybile duct cancer Cholangiocarcinoma

Phase 2

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy

Quintilesbile duct cancer Cholangiocarcinoma

Target: 4Updated: 2024-02-28

Unknown Phase

Toripalimab Combined With Anlotinib for Patients With Advanced, Relapsed, or Refractory Gastric, or Esophagogastric Junction Cancer (EGJC)

The Affiliated Hospital of Qingdao UniversityAdvanced, Relapsed Gastric or Gastro-oesophageal Junction Carcinoma, Gastric or Gastro-oesophageal Junction Carcinoma, Second-line Therapy

Start: 2020-01-01End: 2023-01-01Target: 62Updated: 2021-07-01

Related Papers

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma

The Oncologist2022-07-2017 citations